MTOR and B-cell chronic lymphocytic leukemia: Of note, changes in eEF2 expression/phosphorylation in primary CLL cells isolated fresh ex vivo indicate that peripheral CLL cells possess elevated eEF2 activity and are primed to proliferate in comparison with normal healthy B cells, with treatments containing mTOR inhibitors reducing eEF2 expression in CLL cells.